WO2019013172A1 - Health food containing silkworm cocoon-derived ingredient - Google Patents
Health food containing silkworm cocoon-derived ingredient Download PDFInfo
- Publication number
- WO2019013172A1 WO2019013172A1 PCT/JP2018/025905 JP2018025905W WO2019013172A1 WO 2019013172 A1 WO2019013172 A1 WO 2019013172A1 JP 2018025905 W JP2018025905 W JP 2018025905W WO 2019013172 A1 WO2019013172 A1 WO 2019013172A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fibroin
- sericin
- persimmon
- health food
- cocoon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the diabetes population in Japan is said to be approximately 20 million people including the reserve force, and about 90% of them are due to genetic factors such as hyperphagia (especially high-fat diet), lack of exercise, obesity, metabolic syndrome, stress It is type 2 diabetes that is caused by factors such as lifestyle habits and aging.
- lifestyle modification therapy such as diet and exercise therapy
- drug therapy drugs
- energy intake is determined in consideration of age, obesity, blood sugar level, etc., and overeating, suppressing high-fat food intake, at least 3 to 5 times a week, preferably daily.
- Treatment with exercise of 150 minutes or more (of which 20 to 60 minutes is aerobic exercise with a high load to some extent) is recommended, and even if this lifestyle modification does not reach the target blood glucose level, drug therapy is given.
- the koji-derived component-containing health food of the present example comprises fibroin powder obtained by powdering fibroin obtained from green mochi, sericin powder obtained by powdering sericin obtained similarly from green mochi, and The leaves are mixed with powdered mulberry leaf powder, and the final form thereof is a powder as it is or formed into a solid form such as a tablet or a capsule.
- a sterile sericulture or a rabbit may be adopted (in the present embodiment, a construction in which the sterile sericulture is adopted).
- fibroin and sericin contained in green mulberry, and 1-deoxynojirimycin, Q3MG, calcium, and fibers contained in persimmon leaves, diabetic patients and their preparatory arm and metabolic syndrome subject can be easily and simultaneously taken from various lupus-derived components useful for the treatment of diabetes, thereby suppressing the postprandial increase in blood glucose level due to diabetes, ameliorating metabolic syndrome, and suppressing arteriosclerosis It will be an unprecedented breakthrough that exerts various beneficial effects such as amelioration of undiseased patients.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The purpose of the present invention is to provide a health food containing silkworm cocoon-derived ingredient(s), said health food being efficacious for diabetic patients, pre-diabetic patients and those with metabolic syndrome, with the use of silkworm-derived ingredients (silkworm cocoons and mulberry leaves) that are easily available for sericulturists such as silk-raising farmers and silkworm breeders. A health food containing silkworm cocoon-derived ingredient(s) which contains, as active ingredients, fibroin obtained from silkworm cocoons and/or sericin obtained from silkworm cocoons together with mulberry leaves.
Description
本発明は、蚕の繭から得られるフィブロインやセリシンと、桑の葉を含有する蚕繭由来成分含有健康食品に関するものである。
The present invention relates to a health food containing an anther-derived component containing fibroin and sericin obtained from persimmon leaves and persimmon leaves.
日本における糖尿病人口は、予備軍を含めるとおよそ二千万人いるといわれており、そのうちの約９割は、遺伝的要因に過食（特に高脂肪食）、運動不足、肥満、メタボリック症候群、ストレス等の生活習慣や加齢といった要因が加わり発症する２型糖尿病である。
The diabetes population in Japan is said to be approximately 20 million people including the reserve force, and about 90% of them are due to genetic factors such as hyperphagia (especially high-fat diet), lack of exercise, obesity, metabolic syndrome, stress It is type 2 diabetes that is caused by factors such as lifestyle habits and aging.
この糖尿病の治療には、食事療法、運動療法といった生活習慣改善療法と、薬物療法の大きく分けて二つの治療方法があり、一般的には、初期の段階であれば、まず、前者の生活習慣の改善、具体的には、例えば、年齢、肥満度、血糖値等を考慮してエネルギー摂取量を決定し、過食、高脂肪食摂取を抑えると共に、少なくとも３～５回／週、できれば毎日、１５０分以上の運動（そのうち、２０～６０分はある程度負荷が高い有酸素運動）による治療が勧められ、この生活習慣の改善でも目標の血糖値に達しない場合は、薬物療法が行われる。
There are two major treatment methods for diabetes treatment, lifestyle modification therapy such as diet and exercise therapy, and drug therapy. Generally, in the early stages, the lifestyle habits of the former Specifically, for example, energy intake is determined in consideration of age, obesity, blood sugar level, etc., and overeating, suppressing high-fat food intake, at least 3 to 5 times a week, preferably daily. Treatment with exercise of 150 minutes or more (of which 20 to 60 minutes is aerobic exercise with a high load to some extent) is recommended, and even if this lifestyle modification does not reach the target blood glucose level, drug therapy is given.
この薬物療法では、一般的にはインスリン注射ではなく、飲み薬だけで対応する場合が多く、例えば、インスリンの分泌を促すインクレチン関連薬、スルフォルニ尿素薬、グリニド薬、インスリンの効きを良くするピグマナイド薬、チアゾリジン薬、そして、食後の血糖の上昇を抑えるα－グルコシダーゼ阻害薬などが一般的に用いられる。また、α－グルコシダーゼ阻害薬に関しては、糖尿病患者だけでなく、糖尿病予備軍である境界型の人にも予防的に使用されることもある。
In this medication, in general, it is not insulin injection but often taken only by taking a drug. For example, incretin-related drugs that promote the secretion of insulin, sulforniurea drugs, glinide drugs, pigmanoids that improve the efficacy of insulin Drugs, thiazolidine drugs, and α-glucosidase inhibitors that suppress the increase in postprandial blood glucose are generally used. In addition, with regard to α-glucosidase inhibitors, they may be used prophylactically not only for diabetic patients but also for borderline persons who are a diabetes preparatory force.
このような血糖値上昇抑制剤に関しては、近年、桑の葉に含まれる１－デオキシノジリマイシン（ＤＮＪ）に血糖値の上昇を抑制する効果があることが確認され、この桑の葉を有効成分とした血糖値上昇抑制剤や健康補助食品に関する研究が進み、例えば特許文献１～４のような様々な血糖値上昇抑制剤や健康補助食品に関する特許出願がなされている。
With regard to such a blood sugar level elevation inhibitor, it has recently been confirmed that 1-deoxynojirimycin (DNJ) contained in persimmon leaves has an effect of suppressing a rise in blood sugar level, and the persimmon leaves are used as an active ingredient. Researches on blood sugar level elevation inhibitors and health supplements have been advanced, and patent applications have been made on various blood sugar level elevation inhibitors and health supplements, such as Patent Documents 1 to 4, for example.
また、この桑の葉を餌とする蚕が産生する絹糸（シルク）は、フィブロインとセリシンとの二種類のタンパク質で構成されるものであり、主成分であるフィブロインは、従来、セリシンを除去した後、繊維用途（絹糸）に利用されるのが一般的であったが、近年、このフィブロインのタンパク質としての研究が進み、医薬品、食品分野に応用されるようになり、食べるシルクとして注目を集めている。
In addition, silk thread (silk) produced by mulberry that feeds on mulberry leaves is composed of two kinds of proteins of fibroin and sericin, and fibroin, which is the main component, has conventionally removed sericin After that, it was common to be used for textile application (silk thread), but in recent years, research on this fibroin as protein progressed, and it came to be applied to pharmaceuticals and food fields, and attracted attention as eating silk ing.
この蚕の絹糸（繭）から得られるフィブロイン（シルクフィブロイン）は、高吸脂性であるとともに難消化性であるため、摂取すると体内で脂肪（コレステロール）を吸着し、腸管で吸収されずに脂肪を吸着した状態のまま体外へ排出され、これにより、中性脂肪値の低下作用、血糖値の低下作用、ヘモグロビンＡ１ｃ値の低下作用、コレステロールの低下作用・正常化作用をもたらすことから、ダイエット食品やメタボリック症候群の改善剤、予防剤として用いられている。
Since fibroin (silk fibroin) obtained from silkworm silk (silk fibroin) is highly fat-absorbing and indigestible, it absorbs fat (cholesterol) in the body when ingested, and is not absorbed in the intestinal tract, but it is fat It is excreted from the body as it is adsorbed, thereby providing a lowering effect on neutral fat level, a lowering action on blood glucose level, a lowering action on hemoglobin A1c level, and a lowering action / normalization action on cholesterol. It is used as a remedy for or prevention of metabolic syndrome.
また、フィブロインから分離されたセリシンは、従来、保湿効果、抗酸化活性、チロシナーゼ阻害活性、紫外線カット機能を有することが知られており、主に化粧品関連に用いられていたが、近年、このセリシンに関しても様々な研究が進み、このセリシンには、上記の効果以外に、便秘改善効果、大腸がん発現抑制効果、ミネラル吸収促進作用があることが確認され、前述したフィブロイン同様、医薬品、食品分野にも応用されるようになっている。
In addition, sericin isolated from fibroin is conventionally known to have a moisturizing effect, an antioxidant activity, a tyrosinase inhibitory activity, and an ultraviolet ray cut function, and was mainly used in cosmetics, but in recent years, this sericin In addition to the above effects, sericin has been confirmed to have constipation improvement effects, colon cancer expression suppressive effects, and mineral absorption promotion effects, as well as fibroin as described above, as well as pharmaceuticals and food fields. It is also applied to
このように、蚕に関連した素材（成分）には糖尿病患者やその予備軍、更にはメタボリック症候群対象者に対して有効な改善・予防効果を発揮する有用成分が含まれている。
Thus, materials (components) related to hemorrhoids include useful components that exert an effective ameliorating / preventing effect on patients with diabetes and their armed forces, as well as in persons with metabolic syndrome.
ところで、前述したように、繭は蚕が産生するものであるから、養蚕を営むもの（例えば養蚕農家や養蚕事業者）であれば、これら蚕由来成分（蚕の繭や桑の葉）は極めて容易に入手することが可能である。
By the way, as described above, since salmon is produced by salmon, if it is a farmer engaged in sericulture (for example, a sericulture farmer or a sericulture company), these salmon derived components (carp salmon or salmon leaf) are extremely It is easy to obtain.
本発明者は、養蚕事業の一環として、容易に入手することが可能な蚕の繭や桑の葉を用い、容易に且つ安価に新たな健康食品を製造することができると考え、本発明を見出した。
The inventor of the present invention considers that the present invention can be easily and inexpensively manufactured as a new health food by using easily available persimmon koji or kaki leaf as part of a sericulture business. I found it.
即ち、本発明は、養蚕農家や養蚕事業者などの養蚕を営むものが容易に入手可能な蚕由来成分（蚕の繭や桑の葉）を用い、糖尿病患者やその予備軍並びにメタボリック症候群対象者に対して有用な蚕繭由来成分含有健康食品を提供することを目的とする。
That is, according to the present invention, a diabetic patient or a preparatory army or a person who is a subject of metabolic syndrome are used, using a salmon-derived component (a salmon roe or a mulberry leaf) which can be easily obtained by those engaged in sericulture such as a sericulture farm It is an object of the present invention to provide a health food containing a koji-derived component that is useful for
本発明の要旨を説明する。
The gist of the present invention will be described.
蚕の繭から得られるフィブロイン、又は蚕の繭から得られるセリシンの少なくともいずれか一方と、桑の葉とを有効成分として含有することを特徴とする蚕繭由来成分含有健康食品に係るものである。
The present invention relates to a health food containing a cocoon-derived component, comprising at least one of fibroin obtained from cocoon of cocoon and sericin obtained from cocoon of cocoon, as an active ingredient. .
また、蚕の繭から得られるフィブロインと、蚕の繭から得られるセリシンと、桑の葉とを有効成分として含有することを特徴とする蚕繭由来成分含有健康食品に係るものである。
The present invention also relates to a cocoon-derived component-containing health food characterized by containing fibroin obtained from cocoon of the cocoon, sericin obtained from cocoon of the cocoon, and bamboo leaves as active ingredients.
また、前記フィブロイン、前記セリシン、及び前記桑の葉は、粉末化されているものであることを特徴とする請求項２記載の蚕繭由来成分含有健康食品に係るものである。
In addition, the fibroin, the sericin, and the persimmon leaf are powdered, which relates to the persimmon-derived component-containing health food according to claim 2.
本発明は上述のように構成したから、蚕の繭に含まれるフィブロインやセリシンといった糖尿病患者やその予備軍並びにメタボリック症候群対象者に対して有用な成分と、桑の葉に含まれる豊富な１－デオキシノジリマイシンを、容易に且つ同時に摂取することができる。
Since the present invention is configured as described above, fibroin and sericin contained in the cocoon of the cocoon, a component useful for diabetic patients and their preparatory armies and metabolic syndrome subjects, and rich in cocoon leaf 1 Deoxynojirimycin can be taken easily and simultaneously.
また、本発明は、例えば養蚕事業者が実施すれば、蚕の繭は自身が生産しているものであるから容易に入手可能であるし、また、桑の葉も蚕の餌としてその入手手段が確立されているので容易に入手することが可能であり、よって、原材料費、流通費などの製造コストを抑えることができるので、製品を安価に提供することが可能となる。
In addition, according to the present invention, for example, if a sericulture company implements, salmon persimmons can be easily obtained since they are produced by themselves, and persimmon leaves can also be obtained as bas-relief food. Since it is possible to obtain easily because it is established, it is possible to reduce the manufacturing costs such as raw material costs and distribution costs, so it is possible to provide products inexpensively.
好適と考える本発明の実施形態を、本発明の作用を示して簡単に説明する。
The preferred embodiments of the present invention will be briefly described showing the operation of the present invention.
本発明を摂取することで、蚕の繭由来のフィブロインやセリシンと、桑の葉由来の１－デオキシノジリマイシンとを同時に摂取することができ、各成分が夫々有効に作用する。
By taking the present invention, fibroin and sericin derived from persimmon persimmon and 1-deoxynojirimycin derived from persimmon leaf can be simultaneously ingested, and each component works effectively.
即ち、例えば、フィブロインとセリシンの両方を含有する構成とすれば、本発明の摂取により、フィブロインにより脂肪の蓄積が抑制され、更に、セリシンにより便秘が改善され、ミネラルの吸収も促進されるので、肥満体質の改善が図られ、メタボリック症候群の予防又は改善が図られる。
That is, for example, when the composition contains both fibroin and sericin, the intake of the present invention suppresses the accumulation of fat by fibroin, and further improves the constipation by sericin and promotes the absorption of minerals, Obesity is improved and metabolic syndrome is prevented or ameliorated.
また、桑の葉由来の１－デオキシノジリマイシンにより糖の腸からの吸収が抑制されて食後の血糖値の急激な上昇が抑制されるので、糖尿病の症状が緩和される。
In addition, 1-deoxynojirimycin derived from persimmon leaves suppresses absorption of sugar from the intestine and suppresses a rapid rise in blood glucose level after meals, thereby alleviating the symptoms of diabetes.
また、本発明は、養蚕事業者であれば、その原材料となる蚕の繭は自給することができ、また、桑の葉も蚕の飼料として容易に入手可能なので、原材料費、流通費などの製造コストを抑えることができ、製品を安価に提供することが可能となる。
In the present invention, if it is a sericulture company, it can self-supply the persimmon leaf which is the raw material, and since persimmon leaves are easily available as feed for persimmon, raw material costs, distribution costs, etc. The manufacturing cost can be reduced, and the product can be provided inexpensively.
本発明の具体的な実施例について説明する。
Specific examples of the present invention will be described.
本実施例は、蚕の繭から得られるフィブロインと、蚕の繭から得られるセリシンと、桑の葉とを有効成分として含有する蚕繭由来成分含有健康食品である。
A present Example is a persimmon origin component containing health food which contains fibroin obtained from persimmon koji, sericin obtained from persimmon koji, and a persimmon leaf as an active ingredient.
具体的には、本実施例の蚕繭由来成分含有健康食品は、みどり繭から得られるフィブロインを粉末化したフィブロイン粉末と、同様にみどり繭から得られるセリシンを粉末化したセリシン粉末と、桑の葉を粉末化した桑の葉粉末とが混合されてなり、その最終形態は、粉末のまま、若しくは、錠剤又はカプセル剤など固形状に形成されてなるものである。
Specifically, the koji-derived component-containing health food of the present example comprises fibroin powder obtained by powdering fibroin obtained from green mochi, sericin powder obtained by powdering sericin obtained similarly from green mochi, and The leaves are mixed with powdered mulberry leaf powder, and the final form thereof is a powder as it is or formed into a solid form such as a tablet or a capsule.
より具体的には、本実施例のフィブロイン粉末とセリシン粉末は、みどり繭をそのまま凍結乾燥機にて予備凍結（－４５℃、３時間）し、この予備凍結したみどり繭を乾燥（４０℃、０．１Ｔｏｒｒ、２６時間）して凍結乾燥状態にし、この凍結乾燥状態となったみどり繭を粉砕機で粉砕して粉末化して得られるみどり繭粉末である。
More specifically, the fibroin powder and the sericin powder of this example are pre-frozen (-45 ° C., 3 hours) as they are in a lyophilizer, and the pre-frozen green potato is dried (40 ° C., 0.1 torr, 26 hours) to obtain a freeze-dried state, and the freeze-dried state green leaf is obtained by grinding and pulverizing with a grinder.
即ち、本実施例のフィブロイン粉末及びセリシン粉末は、みどり繭そのものを粉末化したみどり繭粉末であり、みどり繭が本来含んでいるフィブロイン、セリシンの双方の成分をそのまま含有するものである。
That is, the fibroin powder and the sericin powder of the present example are green potato powder obtained by powdering green potato per se, and it directly contains both components of fibroin and sericin originally contained in the green potato.
また、上記方法では原材料となるみどり繭の総重量に対して得られるみどり繭粉末の割合（繭重量回収率）は約８０％である。また、みどり繭の平均重量は約４００ｇであるから、本実施例のみどり繭粉末、すなわち、フィブロイン粉末及びセリシン粉末を１ｇ得るには、およそ３個のみどり繭が必要となる。即ち、言い換えると、本実施例のみどり繭粉末１ｇあたり、およそ３個分のみどり繭の有用成分が含まれることとなる。
Further, in the above method, the proportion (green matter weight recovery rate) of green soda powder obtained with respect to the total weight of green soda as a raw material is about 80%. In addition, since the average weight of the green mochi is about 400 g, about 3 pieces of mochi mochi are required to obtain 1 g of the green mochi powder, that is, fibroin powder and sericin powder in this example. That is, in other words, about 3 pieces of useful ingredients of a weir are included per 1 g of the weir powder of this example.
なお、本実施例では、上述のようにみどり繭を採用する構成とされているが、繭は、これに限定されるものではなく、白繭でも良い。
In the present embodiment, as described above, green rice cake is adopted, but the rice cake is not limited to this and may be white rice cake.
また、この繭を産生する蚕についても、無菌養蚕、家蚕のいずれのものを採用する構成としても良い（本実施例では、無菌養蚕を採用した構成とされている。）。
In addition, as to the koji producing this koji, either a sterile sericulture or a rabbit may be adopted (in the present embodiment, a construction in which the sterile sericulture is adopted).
また、本実施例では、フィブロイン粉末とセリシン粉末をみどり繭粉末として予め混合されている状態のものが採用されているが、公知の方法により、繭からフィブロインを抽出し、更にこのフィブロインからセリシンを分離抽出し、夫々を別々に粉末化しても良い。
Also, in this embodiment, fibroin powder and sericin powder are mixed in advance as green coffee powder, but fibroin is extracted from coffee by a known method, and sericin is further extracted from the fibroin. It may be separated and extracted, and each may be powdered separately.
また更に、粉末化する前にペプチド化し、このペプチド化したものを粉末化しても良い。
Furthermore, it may be peptidized before being powdered, and this peptidized product may be powdered.
また、本実施例の桑の葉粉末は、一般的な茶葉を製造する方法と同法（本実施例では、裁断した生の桑の葉を蒸して殺菌した後、乾燥機にて乾燥（約１００℃））で乾燥状態にし、この乾燥状態となった桑の葉を粉砕機で粉砕して粉末化したものである。
In addition, the persimmon leaf powder of this example is the same method for producing general tea leaves (in this example, after cutting the raw persimmon leaf which has been cut and steamed and disinfected, it is dried with a dryer (about It is made to be in a dry state at 100 ° C.), and the dried mulberry leaves are crushed and pulverized by a grinder.
また、上記方法では原材料となる桑の葉（乾燥桑の葉）の総重量に対して得られる桑の葉粉末の割合（桑の葉重量回収率）はほぼ１００％である。よって、桑の葉１ｇ（小さい桑の葉１枚分程度）から１ｇの桑の葉粉末が得られる。
Further, in the above method, the ratio of mulberry leaf powder to be obtained to the total weight of persimmon leaf (dried persimmon leaf), which is the raw material, is about 100%. Therefore, 1 g of persimmon leaf powder can be obtained from 1 g of persimmon leaf (about one small persimmon leaf).
本実施例の蚕繭由来成分含有健康食品は、上述のみどり繭粉末（フィブロイン粉末及びセリシン粉末）と桑の葉粉末が１：１の混合比で混合されてなる混合粉末が経口用カプセルに充填されてなるカプセル剤として形成されたものである。
The health food of the present embodiment contains the mixed powder obtained by mixing the above-mentioned Midori-don powder (fibroin powder and sericin powder) and persimmon leaf powder at a mixing ratio of 1: 1 into an oral capsule. Formed as a capsule.
このように、本実施例は、蚕の繭に含まれるフィブロインとセリシン、そして、蚕が餌として摂取する桑の葉を主成分とする蚕繭由来成分含有健康食品であるから、本実施例を摂取することで、フィブロイン、セリシン、桑の葉成分を同時に摂取することができる。そして、例えば、糖尿病患者やその予備軍が本実施例を摂取することで、みどり繭粉末に含まれるフィブロイン（シルクフィブロイン）の効果による中性脂肪値の低下、ヘモグロビンＡ１ｃ値の低下、コレステロールの低下・正常化と、セリシンの効果による便秘改善、ミネラル吸収促進などがもたらされ、更に、桑の葉に含まれる１－デオキシノジリマイシンの効果により、食後の血糖値の上昇が抑制され、糖尿病の症状が緩和されるだけでなく、メタボリック症候群の改善も図れる。
As described above, since the present example is a health food containing sputum-derived components, which is mainly composed of fibroin and sericin contained in the sputum of the sputum, and a sputum leaf which the sputum ingests as food, the present example By ingesting, fibroin, sericin and persimmon leaf components can be simultaneously ingested. And, for example, when a diabetic patient or a preparatory army thereof ingests the present example, a decrease in triglyceride level, a decrease in hemoglobin A1c value, and a decrease in cholesterol due to the effect of fibroin (silk fibroin) contained in green potato powder・ Normalization, improvement of constipation by sericin effect, promotion of mineral absorption, etc. are brought about, and further, after the effect of 1-deoxynojirimycin contained in persimmon leaves, the postprandial increase in blood glucose level is suppressed and diabetes Not only can the symptoms be alleviated, it can also improve the metabolic syndrome.
また、桑の葉には１－デオキシノジリマイシンだけでなく、カルシウムも豊富（牛乳の２０倍以上）に含まれているので、本実施例を摂取することにより、摂取量が不足気味であるカルシウム成分を極めて容易に摂取することができる。
In addition, since the persimmon leaf is rich in calcium as well as 1-deoxynojirimycin (more than 20 times that of milk), calcium intake is likely to be insufficient by taking this example. The ingredients can be taken very easily.
また、この桑の葉の繊維質はセリシンと同様に便秘改善効果を発揮するので、セリシンによる便秘改善効果をより一層効果的なものとする。
Moreover, since the fiber of this persimmon leaf exerts the constipation improvement effect like sericin, the constipation improvement effect by sericin is made more effective.
また更に、桑の葉にはケルセチン－３－マロニルグルコシド（Ｑ３ＭＧ）が含まれており、このＱ３ＭＧはＬＤＬ（Low-density lipoprotein）の酸化を抑え、悪玉コレステロールの生成を抑制するので、動脈硬化を抑制する効果が得られる。
Furthermore, the persimmon leaf contains quercetin-3-malonyl glucoside (Q3MG), and this Q3MG suppresses the oxidation of low-density lipoprotein (LDL) and suppresses the formation of bad cholesterol, so that it causes arteriosclerosis. The suppressing effect is obtained.
しかも、Ｑ３ＭＧは、肝臓のストレスを改善し、吸収された糖分を筋肉のエネルギー消費に利用して血糖値を低下させるので、この桑の葉に含まれる１－デオキシノジリマイシンとの相乗効果で、糖尿病患者やその予備軍が摂取することで、より一層、食後の血糖値の上昇の抑制効果が得られる。
Moreover, since Q3MG improves liver stress and uses absorbed sugars for energy consumption of muscle to lower blood glucose level, it has a synergistic effect with 1-deoxynojirimycin contained in this persimmon leaf, Ingestion by diabetic patients and their armies can further suppress the postprandial increase in blood glucose levels.
また、本実施例の原材料である、みどり繭と桑の葉は、過剰摂取しても人体に有害な影響を及ぼさないことが確認されており、よって、糖尿病やその予備軍でない健康な人も安心して摂取することができ、これら健康な人が摂取することで、高血圧、メタボリック症候群、糖尿病の予防に効果が発揮され、健康維持が図られる。
In addition, it has been confirmed that even if you take too much green beans and persimmon leaves, which are the raw materials of this example, harmful effects on the human body will not be adversely affected, and therefore healthy people who are not diabetic or their spare armies. It can be taken safely, and when taken by these healthy people, it is effective in preventing hypertension, metabolic syndrome and diabetes, and health maintenance can be achieved.
このように、本実施例は、みどり繭に含まれるフィブロイン及びセリシン、そして、桑の葉に含まれる１－デオキシノジリマイシン、Ｑ３ＭＧ、カルシウム、繊維質といった糖尿病患者やその予備軍並びにメタボリック症候群対象者に対して有用な種々の蚕由来成分を、容易に且つ同時に摂取することができ、これにより、糖尿病による食後の血糖値上昇を抑制したり、メタボリック症候群を改善したり、動脈硬化を抑制したり、或いは未病の改善など様々な有益な効果を発揮する従来に無い画期的なものとなる。
Thus, in this example, fibroin and sericin contained in green mulberry, and 1-deoxynojirimycin, Q3MG, calcium, and fibers contained in persimmon leaves, diabetic patients and their preparatory arm and metabolic syndrome subject Can be easily and simultaneously taken from various lupus-derived components useful for the treatment of diabetes, thereby suppressing the postprandial increase in blood glucose level due to diabetes, ameliorating metabolic syndrome, and suppressing arteriosclerosis It will be an unprecedented breakthrough that exerts various beneficial effects such as amelioration of undiseased patients.
しかも、本実施例は、養蚕事業者であれば、その原材料となる繭、桑の葉のいずれもが容易に入手することが可能なので、原材料費、流通費などの製造コストを抑えることができ、製品を安価に提供することが可能となる。
Moreover, in the present embodiment, if it is a sericulture business operator, both raw materials persimmon and persimmon leaves can be easily obtained, so that manufacturing costs such as raw material costs and distribution costs can be reduced. , It will be possible to provide products inexpensively.
尚、本実施例では、繭（フィブロインとセリシン）、桑の葉を原材料としたが、例えば、フィブロインと桑の葉、或いは、セリシンと桑の葉の組み合わせとしても良い。また、更に、ミドリムシ（ユーグレナ）を加えても良い。このミドリムシは、中性脂肪やコレステロール等の有害物質を吸着し体外へ排出するデトックス効果を得られるものとして近年注目されており、このミドリムシを更に加えることで、相乗的な効果が発揮され、より一層優れた作用効果が期待できる。
In the present embodiment, mulberry (fibroin and sericin) and mulberry leaves are used as raw materials, but for example, fibroin and mulberry leaves or a combination of sericin and mulberry leaves may be used. In addition, Midorimu (Euglena) may be added. It has been noted in recent years as a detoxifying agent that adsorbs harmful substances such as neutral fat and cholesterol and removes it from the body in recent years. Better effects can be expected.
また、本実施例における各粉末の混合割合は、本実施例に記載の割合に限定されるものではなく、適宜変更可能なものとする。
Further, the mixing ratio of each powder in the present embodiment is not limited to the ratio described in the present embodiment, and can be appropriately changed.
また、本発明は、本実施例に限られるものではなく、各構成要件の具体的構成は適宜設計し得るものである。
Further, the present invention is not limited to the present embodiment, and the specific configuration of each component can be appropriately designed.
Claims (3)
- 蚕の繭から得られるフィブロイン、又は蚕の繭から得られるセリシンの少なくともいずれか一方と、桑の葉とを有効成分として含有することを特徴とする蚕繭由来成分含有健康食品。 A health food comprising an anther-derived component comprising, as active ingredients, at least one of fibroin obtained from anther of a persimmon, or sericin obtained from a persimmon, and a persimmon leaf.
- 蚕の繭から得られるフィブロインと、蚕の繭から得られるセリシンと、桑の葉とを有効成分として含有することを特徴とする蚕繭由来成分含有健康食品。 A cocoon-derived component-containing health food comprising fibroin obtained from cocoon sputum, sericin obtained from cocoon sputum and kaki leaf as active ingredients.
- 前記フィブロイン、前記セリシン、及び前記桑の葉は、粉末化されているものであることを特徴とする請求項２記載の蚕繭由来成分含有健康食品。 The said fibroin, the said sericin, and the said persimmon leaf are powdered, The persimmon origin component containing health food of Claim 2 characterized by the above-mentioned.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017136148A JP2019017264A (en) | 2017-07-12 | 2017-07-12 | Silkworm cocoon-derived component-containing health food |
| JP2017-136148 | 2017-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2019013172A1 true WO2019013172A1 (en) | 2019-01-17 |
Family
ID=65002023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2018/025905 WO2019013172A1 (en) | 2017-07-12 | 2018-07-09 | Health food containing silkworm cocoon-derived ingredient |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2019017264A (en) |
| WO (1) | WO2019013172A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115252677A (en) * | 2022-05-18 | 2022-11-01 | 浙江省农业科学院 | Mulberry leaf prebiotics for regulating and controlling blood glucose homeostasis based on intestinal prebiotics and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7041899B2 (en) * | 2020-01-18 | 2022-03-25 | 株式会社 きものブレイン | Beauty sheet |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004269395A (en) * | 2003-03-07 | 2004-09-30 | Minato Pharmaceutical Co Ltd | Hypotensive action-having composition |
| JP2012125245A (en) * | 2010-12-16 | 2012-07-05 | Industry-Academic Cooperation Foundation Chonnam National Univ | Composition for manufacturing gluten-free rice noodle with hypoglycemic functionality, and production method thereof |
| CN103446503A (en) * | 2013-07-26 | 2013-12-18 | 杨德俊 | Traditional Chinese medicine composition for treating type II diabetes mellitus |
| JP2018126126A (en) * | 2017-02-09 | 2018-08-16 | 株式会社 きものブレイン | Silkworm-derived component-containing dietary supplement and method for producing the same |
-
2017
- 2017-07-12 JP JP2017136148A patent/JP2019017264A/en active Pending
-
2018
- 2018-07-09 WO PCT/JP2018/025905 patent/WO2019013172A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004269395A (en) * | 2003-03-07 | 2004-09-30 | Minato Pharmaceutical Co Ltd | Hypotensive action-having composition |
| JP2012125245A (en) * | 2010-12-16 | 2012-07-05 | Industry-Academic Cooperation Foundation Chonnam National Univ | Composition for manufacturing gluten-free rice noodle with hypoglycemic functionality, and production method thereof |
| CN103446503A (en) * | 2013-07-26 | 2013-12-18 | 杨德俊 | Traditional Chinese medicine composition for treating type II diabetes mellitus |
| JP2018126126A (en) * | 2017-02-09 | 2018-08-16 | 株式会社 きものブレイン | Silkworm-derived component-containing dietary supplement and method for producing the same |
Non-Patent Citations (3)
| Title |
|---|
| MINATO HEALTH FOOD WEBSITE, 2007, Retrieved from the Internet <URL:http://www.minatoshiki.com/index.html> [retrieved on 20180903] * |
| MINATO HEATH FOOD: MINATO-TYPE MULBERRY GREEN JUICE, 2007, Retrieved from the Internet <URL:http://www.minatoshiki.com/minato/min ato.html> [retrieved on 20180903] * |
| SUZUKI, KOICHI ET AL.: "Therapy and drug development (no. 3) based on biology using insects as sources: Moraceae silk is natural tonic", PHARM TECH JAPAN, vol. 30, no. 3, 2014, pages 87 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115252677A (en) * | 2022-05-18 | 2022-11-01 | 浙江省农业科学院 | Mulberry leaf prebiotics for regulating and controlling blood glucose homeostasis based on intestinal prebiotics and preparation method thereof |
| CN115252677B (en) * | 2022-05-18 | 2023-05-12 | 浙江省农业科学院 | Mulberry leaf prebiotics for regulating and controlling blood glucose homeostasis based on intestinal probiotics and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019017264A (en) | 2019-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7976880B2 (en) | Pregnane glycoside compositions and Caralluma extract products and uses thereof | |
| JP7069490B2 (en) | Yuricoma longifolia extract and its use in enhancing and / or stimulating the immune system | |
| JP2016128471A (en) | Use of compositions and formulations for increasing ratio of gastrointestinal tract microbiota of bacteroidetes to microbiota of firmicutes | |
| RU2646459C2 (en) | Compositions for obesity treating and preventing | |
| KR101695848B1 (en) | A composition comprising ginsenoside f2 for preventing or treating non-alcoholic liver disease | |
| WO2019013172A1 (en) | Health food containing silkworm cocoon-derived ingredient | |
| CN107530320A (en) | Muscle fatization suppression composition | |
| AU2013313720B2 (en) | Methods and uses of an extract from olive leaf in management of type 2 diabetes | |
| KR20110105627A (en) | Anti-obesity composition containing silkworm hemolymph | |
| JP2018126126A (en) | Silkworm-derived component-containing dietary supplement and method for producing the same | |
| KR20210104952A (en) | Functional health food for defecaation inducement and diet | |
| KR101923603B1 (en) | A composition for anti-obesity comprising green tea complex extracts | |
| WO2018117103A1 (en) | Composition for ameliorating peripheral nerve disorders | |
| JP2019210269A (en) | Composition for treating diabetic disease | |
| KR20160070912A (en) | A composition for the prevention or treatment of abnormal weight loss comprising Citrus Unshiu Peel extract | |
| KR20140017933A (en) | Composition comprising fermented extract of trifoliate orange for improving diabetes | |
| WO2014016265A1 (en) | Hawthorn and phytosterols and their effect on metabolic disorders | |
| WO2009093353A1 (en) | Medicinal composition | |
| Sankpal et al. | Coffea arabica: Herbal drug on Global health issue-obesity | |
| Cantisani et al. | Unusual Food Allergy: AlioideaAllergic Reactions Overview | |
| JP2018502893A (en) | Chlorophyll composition | |
| KR101241455B1 (en) | Bean curd having hypotensive effect | |
| JP2016040314A (en) | Oral pharmaceutical composition and functional food | |
| JP6378926B2 (en) | Composition for lowering blood glucose level | |
| KR102609638B1 (en) | Composition comprising underia pinnatifida sporophyll hot-water extract for improving gut microbiome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18832765 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18832765 Country of ref document: EP Kind code of ref document: A1 |